Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livmoniplimab + Budigalimab in Advanced/Metastatic HCC
NCT06109272Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of livmoniplimab in hepatocellular carcinoma (HCC), sponsored by AbbVie Inc.. Started Jan 2024; status: active, not recruiting.
02
Drugs
livmoniplimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06109272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109272.